Drugs / Delcetravir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05453279 | Sep → Nov 2022 | COVID-19 | Esfam Biotech Pty Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Delcetravir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05453279 ↗ |
| Action | Inhibit | “an inhaled COVID-19 Inhibitor Delcetravir” NCT05453279 ↗ |